Clinical Trial Data, New Publications, Promotions, Financial Results and FDA Acknowledgements - Research Report on Gilead, Amgen, ACADIA Pharmaceuticals, ViroPharma, and MannKind

Wed Nov 6, 2013 8:00am EST

* Reuters is not responsible for the content in this press release.

Clinical Trial Data, New Publications, Promotions, Financial Results and FDA Acknowledgements - Research Report on Gilead, Amgen, ACADIA Pharmaceuticals, ViroPharma, and MannKind

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, November 6, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Gilead Sciences, Inc. (NASDAQ: GILD), Amgen, Inc. (NASDAQ: AMGN), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), ViroPharma Incorporated (NASDAQ: VPHM), and MannKind Corporation (NASDAQ: MNKD). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Gilead Sciences, Inc. Research Report

On November 2, 2013, Gilead Sciences, Inc. (Gilead) announced results from a Phase 3 study, PHOTON-1, which evaluated the investigational once-daily nucleotide analogue sofosbuvir for the treatment of chronic hepatitis C virus (HCV) infection among patients co-infected with HIV. According to the results of the trial, 76% of genotype 1 HCV treatment naïve patients receiving 24 weeks of an all-oral, interferon-free regimen of sofosbuvir plus ribavirin (RBV) achieved a sustained virologic response 12 weeks after completing therapy (SVR12). The Company stated that patients who achieve SVR12 are considered cured of HCV infection. Douglas Dieterich, MD, Professor of Medicine in the Division of Liver Diseases and Director of Continuing Medical Education in the Department of Medicine at Mount Sinai School of Medicine said, "In this study, sofosbuvir-based all-oral therapy achieved high SVR rates in a hard-to-treat patient population. This regimen may have the potential to help us overcome the clinical challenge of treating HCV/HIV co-infection." The Full Research Report on Gilead Sciences, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/9898_GILD]

--

Amgen, Inc. Research Report

On October 24, 2013, Amgen, Inc. (Amgen) announced the promotion of two senior executives, Brian McNamee and Stuart Tross, to the positions of Executive Vice President and Senior Vice President, respectively, effective as of November 1, 2013. In the new positions, McNamee will be responsible for leading a series of multi-year initiatives focused on delivering growth and increasing productivity and agility, while Tross will be responsible for the Company's global human resources activities. Both, McNamee and Stuart Tross will report directly to the Company's Chairman and CEO, Robert A. Bradway. The Full Research Report on Amgen, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/e96b_AMGN]

--

ACADIA Pharmaceuticals Inc. Research Report

On October 31, 2013, ACADIA Pharmaceuticals Inc. (ACADIA) announced the publication of data from its pivotal Phase III -020 Study with pimavanserin in patients with Parkinson's disease psychosis (PDP) in the November 1, 2013 online issue of The Lancet. The Company informed that in the -020 Study, pimavanserin demonstrated significant and clinically meaningful benefits and was safe and well tolerated in patients with PDP. Jeffrey Cummings, M.D., Sc.D., Director of Cleveland Clinic Lou Ruvo Center for Brain Health and Lead Author said, "These data indicate that pimavanserin, a selective 5-HT2A inverse agonist, confers a meaningful clinical benefit in patients with PDP and has the potential to be an important new treatment option for this condition for which there is no approved therapy in the U.S." The Full Research Report on ACADIA Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/3eb7_ACAD]

--

ViroPharma Incorporated Research Report

On October 31, 2013, ViroPharma Incorporated (ViroPharma) reported Q3 2013 financial results. In Q3 2013, the Company's net sales totaled $113.1 million, up 24.3% YoY. The Company stated that the increase was primarily driven by growth in US Cinryze sales. GAAP net income was $4.2 million, or $0.06 per diluted share during the quarter, compared with a net loss of $4.6 million, or $0.07 per diluted share, in Q3 2012. "We continue to generate strong growth in our commercial business, notably led by the acceleration of Cinryze demand here in the United States. Our pipeline also continues to advance, establishing a number of important data points over the next several months," said Vincent Milano, CEO of ViroPharma. The Full Research Report on ViroPharma Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/c730_VPHM]

--

MannKind Corporation Research Report

On October 30, 2013, MannKind Corporation (MannKind) announced that the FDA has acknowledged the Company's resubmission of an NDA for AFREZZA Inhalation Powder. MannKind informed that the FDA considered the updated NDA to be a complete class 2 response to its Complete Response Letter that was issued in January 2011 and assigned a user fee goal date of April 15, 2014. The Full Research Report on MannKind Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/044e_MNKD]

----

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


AnalystsCorner.com

SOURCE Analysts' Corner

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.